Review

Cancer Research

The Tumor Metabolic Microenvironment: Lessons from Lactate

Juan C. García-Cañaveras, Li Chen, and Joshua D. Rabinowitz

Abstract

The extracellular milieu of tumors is generally assumed to be immunosuppressive due in part to metabolic factors. Here, we review methods for probing the tumor metabolic microenvironment. In parallel, we consider the resulting available evidence, with a focus on lactate, which is the most strongly increased metabolite in bulk tumors. Limited microenvironment concentration measurements suggest depletion of glucose and modest accumulation of lactate (less than 2-fold). Isotope tracer measurements show rapid lactate exchange between the tumor and circulation. Such exchange is catalyzed by MCT transporters, which cotransport lactate and protons (H^+). Rapid lactate exchange seems at odds with tumor lactate accumulation. We propose a potential resolution to this paradox. Because of the high pH of tumor cells relative to the microenvironment, H^+-coupled transport by MCTs tends to drive lactate from the interstitium into tumor cells. Accordingly, lactate may accumulate preferentially in tumor cells, not the microenvironment. Thus, although they are likely subject to other immunosuppressive metabolic factors, tumor immune cells may not experience a high lactate environment. The lack of clarity regarding microenvironmental lactate highlights the general need for careful metabolite measurements in the tumor extracellular milieu.

Introduction

Cancerous tumors are heterogeneous mixtures of cells and extracellular matrix (1–3). In addition to the driver cancer cells, tumors frequently contain fibroblasts, immune cells, adipocytes, and endothelial cells (1–5). The diverse cell types within the tumor may support or antagonize one another through direct cell–cell interactions or paracrine signaling. In addition, the cell types may cooperate or compete metabolically. For example, one cell type may release a metabolite that feeds another cell type (6–8). Alternatively, several cell types may fight for access to a single limiting nutrient (9–12). Such nutrient competition could potentially dictate the effectiveness of antitumor immune response.

Although it is clear that tumors are nutrient avid, the extent to which they have a distinct metabolic milieu remains less well proven. The interstitial space, or interstitium, refers to extracellular tissue space (excluding the lumen of blood and lymphatic vessels), including both the extracellular matrix and the interstitial fluid (13, 14). The metabolic composition of the tumor interstitium is determined by: (i) nutrient uptake from the blood supply into the tumor, (ii) nutrient uptake and waste excretion by tumor cells, and (iii) drainage by veins and lymphatics. In normal tissues, rapid exchange of nutrients between the interstitium and blood stream provides cells with reliable nutrient access and waste removal. Establishment of a distinct tumor metabolic microenvironment depends on nutrient consumption and waste production within the tumor overwhelming exchange with the circulation. This could in principle occur due either to the tumor's heightened metabolic activity or to poor perfusion. Here, we review methods for probing the tumor metabolic microenvironment and the somewhat contradictory evidence arising from them. We then propose a potential mechanism for tumor lactate accumulation, which suggests that lactate may localize within tumor cells and therefore not rise to immunosuppressive levels in the extracellular milieu.

Nutrient utilization

What metabolic activity within tumors might yield a distinct microenvironment? The answer goes back to the work of Otto Warburg, who demonstrated avid glucose fermentation into lactate by cancer cells. This raises the potential for the tumor microenvironment to be glucose poor and lactate rich. More recently, glutamine has been recognized as a key substrate for cancer cells, which often in turn secrete glutamate. This phenomenon is in part an artifact of cell culture media containing high cystine, which drives glutamate export via the xCT transporter (15); nevertheless, glutamine depletion is another potential outcome of heightened cancer cell metabolism (16). Other important cancer cell substrates to support biomass and energy production include acetate (17, 18), branched chain amino acids (19), non-essential amino acids (7), and even the canonical tumor waste product lactate (20, 21). In addition, tumor cells can release immunosuppressive metabolites, such as adenosine (22) or the tryptophan catabolite kynurenine (23).

Changes to the extracellular metabolic environment can impact cancer by altering the growth, survival, or phenotype of both cancer cells and other tumor cells, including immune cells. Cancer cells themselves are typically dependent on glucose, and also often glutamine, to grow. Hence, a nutrient-poor microenvironment might slow cancer growth. Unfortunately, the same

Lewis Sigler Institute for Integrative Genomics and Department of Chemistry, Princeton University, Princeton, New Jersey.

Corresponding Author: Joshua D. Rabinowitz, Princeton University, Princeton, NJ 08544. Phone: 609-258-8985; Fax: 609-258-7070; E-mail: joshr@princeton.edu

Cancer Res 2019;79:3155–62

doi: 10.1158/0008-5472.CAN-18-3726

©2019 American Association for Cancer Research.

Downloaded from http://aacrjournals.org/cancerres/article-pdf/79/13/3155/2782852/3155.pdf by guest on 16 October 2024

nutrients play a critical role in immune response (24). For example, glucose is critical to T-cell proliferation and effector function, with genetic experiments showing the essentiality of T-cell glucose uptake via glucose transporter-1 (GLUT1) to mounting of an effective immune response (25). Conversely, lactate can drive T cells toward an immunosuppressive Treg phenotype (26). Similar phenomena occur in macrophages, where the pro-inflammatory M1 macrophages have high glucose consumption, whereas immune suppressive M2 macrophages do not, thriving on either lactate or fatty acids (27). Moreover, amino acids, including glutamine, arginine, and serine, are important nutrients both for cancer cells and for mounting an effective immune response (28–30). Thus, metabolism by both cancer and immune cells within the tumor microenvironment holds the potential for local nutrient depletion and waste buildup. These metabolic changes could advantageously limit tumor growth, while disadvantageously impairing tumor immune response. But does this really happen to a meaningful extent?

pH and pO_2, key regulators of metabolism within the tumor microenvironment

H^+ and O_2 are not canonical metabolites, but pH and pO_2 are key players in the tumor metabolic microenvironment (31–33). Both H^+ and O_2 play a dual role in tumor metabolism. On one hand, they are metabolic products/reactants, whose levels may directly impact reaction flux and thermodynamics. On the other hand, they regulate the expression and activity of important metabolic enzymes (32, 33).

Extracellular acidification has been shown in tumors through several measurement methods, initially by insertion of electrodes (34, 35). Although a direct measurement approach, probe insertion might induce tissue damage (34). Accordingly, noninvasive techniques such as magnetic resonance spectroscopy (MRS), MRI, and positron emission tomography (PET), using both endogenous and exogenous compounds as pH reporters, were developed (36–38). Compared with normal tissue, where $pH_{intracellular} \approx 7.2$ and $pH_{extracellular} \approx 7.4$, these measurement approaches consistently showed an inverted pH gradient in tumors. The intracellular tumor pH is slightly more basic than in normal tissues, although extracellular pH is more acidic ($pH_{intracellular} > 7.4$, $pH_{extracellular} \approx 6.5$-7). Biochemically, this inverted gradient is maintained by the action of various transporters, for example, Na^+/H^+ exchangers, H^+/K^+-ATPases, and Na^+/HCO_3^-cotransporters, in combination with carbonic anhydrases (e.g., CAIX and CAXII), and monocarboxylic transporters (MCT), which cotransport H^+ and monocarboxylic acid compounds such as lactate (31, 32). The maintenance of this inverted gradient has been suggested to provide a dual benefit for cancer cells: (i) intracellular alkalization facilitates increased glycolysis, thereby promoting cancer cell proliferation, especially in hypoxia (39) and (ii) extracellular acidification hampers the development of a proper immune response (40).

Tumor hypoxia involves oxygen partial pressure (pO_2) below 15 mm Hg (41). Hypoxic and/or anoxic areas are estimated to occur in 50% to 60% of locally advanced solid tumors and are heterogeneously distributed within the tumor mass (42). As in the case of pH measurements, initial tumor pO_2 measurements were made using electrodes (43, 44). A variety of approaches are, however, now available. These include measurements of endogenous proteins, such as HIF1α–target proteins CAIX or GLUT1, whose levels rise in hypoxia. In addition, compounds that selectively stain hypoxic cells (e.g., pimonidazole) can be injected. More direct measurements can be made by implanting paramagnetic crystals (whose interaction with oxygen is measured by electron paramagnetic resonance) or oxygen-sensitive fluorescent probes attached to a fiber-optic cable (OxyLite). Moreover, MRI and PET methods have been developed for noninvasive measurement of tumor oxygenation. PET methods usually rely on 2-nitroimidazole compounds (e.g., ^{18}F-fluoromisonidazole). They can enter the cells by passive diffusion where they can be retained due to the formation of reactive species under reducing conditions in a pO_2-dependent manner (42, 45, 46). Primary tumors in the cervix and breast have been shown to have significantly decreased median pO_2 values (8 and 10 mmHg, respectively) compared with normal tissue in the same organ ($pO_2 = 42$ and 65 mmHg, respectively). Tumor hypoxia ($pO_2 < 10$ mmHg) has been identified as an adverse factor in several tumor types with increased risk of metastasis and decreased overall survival (42).

In summary, both hypoxia and the maintenance of an inverted pH gradient ($pH_{intracellular} > pH_{extracellular}$), are well-established features of the tumor microenvironment that may favor tumorigenesis by rewiring tumor metabolism and by suppressing antitumor immunity.

Metabolite concentration changes in tumors

To understand the tumor metabolic milieu, it is of course necessary to look more broadly than O_2 and H^+. Fortunately, advances in mass spectrometry (MS) and NMR now enable routine measurement of several hundreds of metabolites (as well as yet larger numbers of lipids) from resected tumor specimens. Tissue and tumor samples are usually flash-frozen, ground into powder, and extracted, and the extract analyzed (47, 48). Although providing valuable information about the overall metabolite levels within the tumor, these methods do not measure the microenvironment per se.

Moreover, even measurement of overall tumor metabolite levels can be challenging, because metabolite concentrations may rapidly change upon cutting off the tumor blood supply, making fast resection and freezing of metabolism critical. In addition, MS is subject to substantial day-to-day variation in absolute signal intensity. This can be ideally accounted for using isotopic internal standards, but due to the limited availability and stability of such standards, it is often more practical to normalize to the median metabolite signal intensity in a given sample run. In addition, to interpret the data, choice for proper comparator specimen is critical. The most intuitive comparison is between tumor and benign adjacent tissue, and this works well in cases where the tumor and tissue of origin have equivalent cellular density (e.g., liver, kidney, pancreas), but less so when they do not (e.g., lung, breast; refs. 47, 48).

Perhaps due to these technical challenges, or perhaps due to intrinsic biological variability (e.g., across tissues of origin, oncogenic driver mutations, and better and worse-perfused tumor regions; refs. 19, 49–51), tumor metabolomic analyses have given diverse results. Meta-analyses have identified a general trend for most proteogenic amino acids to be increased in tumors (52). In our own studies of pancreas cancer, however, we found a more interesting pattern, with increased concentrations of amino acids used purely for protein synthesis, but lower concentrations of those used also as nucleotide precursors, with glutamine being the most depleted metabolite (53). This pattern of metabolite

Downloaded from http://aacrjournals.org/cancerres/article-pdf/79/13/3155/2782852/3155.pdf by guest on 16 October 2024

levels is consistent with pancreas cancer acquiring amino acid substantially through protein catabolism, highlighting the potential to link metabolite levels to the biology of specific tumor types (53, 54).

In contrast with the inconsistent results for most metabolites, the most consistently upregulated metabolite across diverse tumors is lactate. Moreover, glucose is one of the most consistently downregulated metabolites. Thus, modern technology has confirmed the centrality of the Warburg effect in tumor metabolism (Fig. 1A; refs. 52, 55). A simple interpretation of these bulk tumor measurements is that tumors avidly convert glucose into lactate, which accumulates in the tumor. But do available data support lactate accumulation in the tumor interstitial fluid rather than inside tumor cells? Is the lactate that accumulates into the tumor locally produced?

Direct sampling of tumor interstitial fluid

Tumor interstitial fluid can in principle be sampled by inserting a probe into the tumor *in vivo* or by isolation of interstitial fluid from a piece of resected tumor. Direct interstitial fluid sampling requires implanting a capillary probe with a semipermeable membrane into the tumor. Such methods have been employed more extensively for extracellular neurotransmitter measurements and have had a substantial impact in neuroscience. In one approach, known as ultrafiltration, negative pressure in the probe is used to collect a filtrate of interstitial fluid. Alternatively, in microdialysis, the capillary probe is filled with carrier fluid, into which contents of the interstitial fluid diffuse (56, 57). In ultrafiltration, the nature of the sampled metabolites depends only on the molecular weight cutoff of the semipermeable membrane, but application of negative pressure might mechanically disrupt surrounding cells. In microdialysis, negative pressure is avoided, but carrier fluid could potentially alter ion-coupled metabolite exchange processes and thus the metabolic milieu (57). In both methods, probe implantation requires a surgical intervention, limiting clinical use. Despite their potential imperfections, these methods offer an unparalleled opportunity to obtain extracellular fluid directly from tumor. Key observations can be validated with complementary methods, such as electrochemical probes used in neuroscience for the *in vivo* analysis of brain interstitial fluid (58). The biggest current limitation is the paucity of available data. To our knowledge, only two studies have applied the microdialysis technique to sample tumor interstitial fluid in human patients with cancer. In head and neck cancer, tumors showed about a 2-fold increase in lactate levels compared with mucosa, whereas adequate data were not available to assess glucose in the tumor versus normal mucosal microenvironment (59). In astrocytoma, compared with adjacent brain, interstitial lactate was modestly increased (1.6-fold) and glucose trended lower, but was not significantly depleted (60). No significant changes were found for other measured metabolites (glutamate, glycerol, and pyruvate). Importantly, the measured microenvironmental lactate was lower than those in tumors overall and lower than the levels applied to modulate immune cell function in cell culture experiments (Fig. 1B).

Ex vivo purification of tumor interstitial fluid

Given the technical challenges of probe-based sampling, there is interest in measuring interstitial fluid in resected tumor specimens. In one approach, known as tissue elution, the tissue is cut into small pieces (1–3 mm^3), washed, and incubated in PBS at 37°C in a humidified CO_2 incubator for 1 to 24 hours (61). Although controls have shown that tissue elution does not result in substantial protein leakage, it seems almost inevitable that cells will continue to excrete metabolites. Thus, although the measurements may reveal interesting aspects of tumor metabolism, they seem ineffective for measuring the tumor microenvironment.

More promising, but still problematic, is tissue centrifugation, in which fresh tissue is washed to remove any residual blood, blotted dry, and transferred to a microcentrifuge tube over a nylon mesh. By applying a controlled centrifugation force (e.g., <424 g), the interstitial fluid is collected at the bottom of the tube, whereas the rest of tissue components, including intact cells, are retained (62, 63). Key concerns in this approach are alteration of the microenvironment during sample collection and handling, and leakage of metabolites due to the centrifugal force, a problem that we have observed in preliminary efforts to apply the method. Using this method, which may be skewed by glucose consumption during the tissue collection or handling, glucose concentration in tumor interstitial fluid has mainly been found to be lower than blood or normal tissue (Fig. 1C). The magnitude of the change is highly variable, ranging from insignificant (64) to over 10-fold decreased (24, 65–67). Corresponding lactate data are in most cases not available.

Thus, it appears that some (and perhaps most) tumors consume glucose sufficiently rapidly to outpace perfusion and create a local, glucose-poor microenvironment. Whether extracellular lactate levels increase appreciably is less clear, with reported levels not reaching those known to inhibit immune response, although this may vary with tumor type and region.

Flux measurements and the tumor metabolic microenvironment

Fluxes provide an orthogonal viewpoint on the tumor metabolic environment: What is being consumed? What is being made? And how fast is exchange between the blood stream and the tumor? For glucose, such analyses have confirmed rapid consumption. But for lactate, they have raised new questions.

Measurement of glucose uptake flux using ^{18}F-fluorodeoxyglucose (^{18}F-FDG)-PET is an important clinical tumor imaging modality. ^{18}F-FDG is an analog of glucose that can be taken into cells and retained by phosphorylation, but not further metabolized. Accumulation of ^{18}F-FDG is a hallmark of glycolytic cells and the avid uptake of glucose by the tumor aligns well with the observation that tumors (both in bulk and in interstitial fluid specifically) are glucose poor (Fig. 1D; ref. 68).

Beyond the PET, other techniques can be employed to probe *in vivo* tumor metabolic fluxes. These include (i) arteriovenous blood composition differences, (ii) stable isotope tracers coupled to either MS or NMR detection, and (iii) hyperpolarized MRI. Nutrients are delivered to tissues (and tumors) by arterial blood and waste is removed by venous blood. The difference in metabolite levels between the incoming and outgoing blood (A/V difference) provides a quantitative measure of net metabolite production and consumption by the tumor. Although conceptually simple, this approach requires obtaining mixed venous blood draining the tumor, which can be difficult given the disorganized nature of tumor vasculature (69, 70). Early tumor A/V difference studies by Otto Warburg showed that Jensen's sarcoma transplanted into rats consumed glucose and produced lactate (71). Net glucose consumption by tumors has been confirmed in a wide

Downloaded from http://aacrjournals.org/cancerres/article-pdf/79/13/3155/2782852/3155.pdf by guest on 16 October 2024



Figure 1.
Experimental approaches for understanding the tumor metabolic microenvironment and summary of associated literature data for glucose and lactate.

Downloaded from http://aacrjournals.org/cancerres/article-pdf/79/13/3155/2782852/3155.pdf by guest on 16 October 2024

range of animal models (72–74). In contrast, these studies suggest that tumors may either produce or consume lactate (Fig. 1E). One apparent determinant is the systemic lactate concentration, with a trend for tumors to consume lactate when the incoming lactate concentration is high, and excrete it when the incoming arterial concentration is lower (72, 73).

In addition to these animal experiments, we are aware of two human studies that measured A/V differences across the tumor. In colon cancer, tumors consumed glucose and essential amino acids; showed no consistent uptake or excretion of ketone bodies or free fatty acids, and consistently secreted ammonia, alanine, and lactate (75). In head and neck cancer, all tumors took up glucose, pyruvate, and ketone bodies while lactate was excreted by some and consumed by other tumors (76). Thus, at least some tumors seem to be net lactate consumers.

Infusions of isotope-labeled nutrients provide a means to probe their metabolic fates within the tumor, and to determine the sources of key metabolic products (21, 48, 77, 78). Recent experiments using isotope tracers *in vivo* are substantially revamping our understanding of tumor metabolism. For example, in contrast with the Warburg effect, which focuses exclusively on glucose's catabolism into lactate, tracing experiments using ^{13}C-labeled glucose have shown that tumors actively metabolize carbon from infused glucose into the TCA cycle via both pyruvate carboxylase and pyruvate dehydrogenase, with rates in lung cancer exceeding those in benign adjacent pulmonary tissue (51, 79–82). Even more surprisingly, tumors not only produce lactate, but they also uptake circulating lactate to be used as TCA substrate (Fig. 1F; refs. 20, 21, 51). Indeed, quantitative analysis suggests that, in several murine tumor models and about half of human non–small cell lung tumors, the main way infused glucose enters the tumor TCA cycle is via circulating lactate: The exchange of lactate between the tumor and circulation is so rapid that little of the pyruvate made from glucose via the tumor's upregulated glycolytic pathway actually makes it directly into the TCA cycle. Instead, in these cases, most tumor pyruvate is converted into lactate and excreted, with most of the pyruvate in the tumor coming from circulating lactate made elsewhere in the body (21). Analogous studies of additional human tumor types are needed. Thus, although many tumor cells produce lactate (32, 83), such lactate may be largely released into the circulation, rather than locally feeding other tumor cells.

Consistent with the rapid transport of pyruvate and lactate into and out of the tumor, and their rapid interconversion within tumors, hyperpolarized [1-^{13}C]pyruvate is converted more rapidly to lactate in tumors compared with benign adjacent tissue: Upon infusion of hyperpolarized pyruvate into patients with prostate cancer, biopsy-proven cancerous regions show increased levels of hyperpolarized [1-^{13}C]lactate and an elevated ratio of [1-^{13}C]lactate/[1-^{13}C]pyruvate (84). Collectively, these isotope tracer studies are difficult to align with the finding that lactate is the most elevated metabolite in human tumors (and the common assumption that lactate is elevated in the microenvironment): How can a uniquely high concentration of lactate be maintained within the tumor, if lactate is mixing rapidly between the tumor and circulation?

A potential resolution to the "lactate paradox": the role of pH in lactate transport

We believe that the biochemistry of MCT transporters can explain the coexistence of (i) rapid exchange between tumor and circulating lactate and (ii) elevated lactate within the tumor. Much as phosphorylation is used by the cells to favor glucose uptake and intracellular retention, we propose that pH is similarly used by cancer cells to maintain their lactate pools.

Lactic acid is transported across membrane through a family of MCTs (85). MCTs cotransport a lactate anion (Lac^-) and H^+. Accordingly, at equilibrium, the product of Lac^- and H^+ concentrations (i.e., $[Lac^-][H^+]$) has to be equal among different compartments linked by MCT transporters. Thus, by maintaining low H^+ concentration (high pH), tumor cells accumulate lactate. Specifically, although normal cells typically have an intracellular pH about 0.2 U lower than the extracellular pH, tumor cells may have an intracellular pH about 0.8 U higher than the microenvironment pH. If the lactate concentration in the microenvironment is equivalent to that in the circulation (e.g., due to leaky capillaries), this could lead to a lactate concentration in tumor cells nearly 10-fold higher than in normal cells, based solely on the thermodynamic consequences of the H^+-coupling of MCT transporters (Fig. 2A). The potential for pH gradients to drive lactate into cells has been previously described in the brain (86). An open question remains the mechanism by which high H^+ concentration is maintained in the tumor microenvironment. Nevertheless, pH gradients, through mechanisms unrelated to the Warburg effect, may drive lactate accumulation in tumors.

Speed of lactate exchange versus net transport by MCTs

Another aspect of the biochemistry of MCT transporters may also help to maintain lactate and pH concentration gradients within the tumor while allowing for a fast isotope exchange between tumor and circulating lactate pools: MCT transporters can exchange lactate across the membrane (i.e., importing one molecule of lactate, and exporting a different one) or trade lactate for another MCT substrate like pyruvate, faster than they can net transport lactate in either direction. The underlying biophysics involves the MCT catalytic transport cycle (Fig. 2B). Transporters bound to both H^+ and Lac^- (or another MCT carbon substrate) rapidly undergo a conformational change that exposes the ligands to the opposite site of the membrane. But transporter lacking substrate undergoes the conformational change slowly. Thus, MCT's are more efficient at transporting Lac^- back and forth across the cell membrane than at dissipating lactate concentration gradients (85). Therefore, MCTs are expected to equilibrate labeling patterns (i.e., mixing of lactate molecules of different origin) and relative monocarboxylate levels (e.g., lactate:pyruvate ratio) faster than they dissipate lactate concentration gradients.

Conclusions

Accumulation of immunosuppressive metabolites in the tumor milieu, in particular lactate, is commonly assumed but poorly proven. *In vitro* experiments have shown that lactic acid is a potent inhibitor of antitumor T cells and favors the development of tumor permissive (i.e., immunosuppressive) T_{reg} cells (26, 40, 87). But, limited direct measurements of interstitial fluid lactate suggest relatively modest accumulation, substantially less than levels used in cell culture studies. A/V

Downloaded from http://aacrjournals.org/cancerres/article-pdf/79/13/3155/2782852/3155.pdf by guest on 16 October 2024



Figure 2.
The role of MCT and pH in lactate transport. **A,** Cancer cells maintain a high intracellular pH, relative to the microenvironment through several mechanisms, including the increased expression and activity of acid extruding plasma membrane transporters, for example, Na^+/H^+ exchangers (NHE), H^+/K^+-ATPases, and Na^+/HCO_3^- cotransporters (NBC), which work in concert with carbonic anhydrases (CA). The generated pH gradient favors the accumulation of lactate inside the cell, as monocarboxylate transporters (MCT) cotransport lactate and H^+, so low intracellular H^+ concentration favors lactate flux into the cell (to equilibrate the product of $[H^+] \times [Lac^-]$ across the membrane). **B,** To mediate lactic acid transport, MCTs bind and release the ligands in an ordered way. The transporters bind sequentially H^+ and Lac^-. Then a conformational change exposes the ligands to the opposite site of the membrane, Lac^- and H^+ are sequentially released, and finally the empty transporter returns to the initial position. The return of the empty transporter to the initial position is the rate-limiting step in the transport process. Therefore, MCTs transport Lac^- back and forth across the membrane more rapidly than they net transport lactate.

gradient measurements suggest that some tumors actually net consume lactate. Isotope tracer studies argue for equilibration of lactate between the circulation and tumor microenvironment (i.e., that the tumor microenvironment is well-perfused from the perspective of lactate, if not from the perspective of oxygen). Even though lactate accumulates within tumor cells, such lactate is "hidden" from immune cells and unlikely to impact immune response. This does not discount the importance of lactate dehydrogenase A expression in cancer cells, which has been shown experimentally to favor tumor immune escape (87), perhaps by enabling rapid cancer glucose consumption. Indeed, even if lactate is mainly in tumor cells, not the environment, low glucose, oxygen, and/or pH in the microenvironment may nevertheless be immunosuppressive (24, 40, 65, 66, 88).

Can we extract any general conclusion about the metabolic composition of tumor microenvironment and its significance for tumor growth and progression? The strongest conclusion is that we need to more carefully characterize the tumor metabolic milieu. This is particularly critical because, due to active transport processes, the metabolic composition of the microenvironment may differ markedly from that of the bulk tumor. Direct interstitial fluid sampling followed by metabolomic analysis seems a valuable step in this direction.

Note Added in Proof

Metabolomics analysis of murine tumor interstitial fluid (isolated via centrifugation) was recently reported, with lactate concentration indistinguishable from plasma (89).

Disclosure of Potential Conflicts of Interest

J.D. Rabinowitz has ownership interest (including stock, patents, etc.) in Agios, Raze Therapeutics, L.E.A.F, Kadmon Pharmaceuticals, Bantam Pharmaceuticals and is a consultant/advisory board member for Kadmon Pharmaceuticals, Agios, L.E.A.F., Bantam Pharmaceuticals, Raze Therapeutics. No potential conflicts of interest were disclosed by the other authors.

Acknowledgments

We thank members of the Rabinowitz laboratory for comments and suggestions. This work was supported by funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 751423 (to J.C. García-Cañaveras), the Rutgers Cancer Institute of New Jersey (P30CA072720 to J.D. Rabinowitz), and the US National Institutes of Health (R01CA163591 to J.D. Rabinowitz). Research supported by a Stand Up To Cancer-Cancer Research UK-Lustgarten Foundation Pancreatic Cancer Dream Team Research Grant (Grant Number: SU2C-AACR-DT20-16 to J.D. Rabinowitz). Stand Up To Cancer is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C.

Received November 26, 2018; revised February 15, 2019; accepted April 10, 2019; published first June 6, 2019.

Downloaded from http://aacrjournals.org/cancerres/article-pdf/79/13/3155/2782852/3155.pdf by guest on 16 October 2024

References

1. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010;18:884–901.
2. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci 2012;125:5591–6.
3. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21:309–22.
4. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423–37.
5. Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T-cell activity: a case for synergistic therapies. Cancer Cell 2017;31:311–25.
6. Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, et al. Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth. Cell Metab 2016;24:685–700.
7. Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature 2016;536:479–83.
8. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011;17:1498–503.
9. Lyssiotis CA, Kimmelman AC. Metabolic interactions in the tumor microenvironment. Trends Cell Biol 2017;27:863–75.
10. Sugiura A, Rathmell JC. Metabolic Barriers to T-function in tumors. J Immunol 2018;200:400–7.
11. Vander Heiden MG, DeBerardinis RJ. Understanding the Intersections between metabolism and cancer biology. Cell 2017;168:657–69.
12. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab 2016;23:27–47.
13. Wiig H, Swartz MA. Interstitial Fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev 2012;92:1005–60.
14. Wagner M, Wiig H. Tumor interstitial fluid formation, characterization, and clinical implications. Front Oncol 2015;5:1–12.
15. Tardito S, Oudin A, Ahmed SU, Fack F, Keunen O, Zheng L, et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat Cell Biol 2015;17:1556–68.
16. Pan M, Reid MA, Lowman XH, Kulkarni RP, Tran TQ, Liu X, et al. Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat Cell Biol 2016;18:1090–101.
17. Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 2014;159:1603–14.
18. Comerford SA, Huang Z, Du X, Wang Y, Cai L, Witkiewicz AK, et al. Acetate dependence of tumors. Cell 2014;159:1591–602.
19. Mayers JR, Torrence ME, Danai L V, Davidson SM, Bauer MR, Lau AN, et al. Tissue-of-origin dictates branched-chain amino acid metabolism in mutant kras -driven cancers. Science 2017;353:1161–5.
20. Faubert B, Li KY, Cai L, Hensley CT, Kim J, Zacharias LG, et al. Lactate metabolism in human lung tumors. Cell 2017;171:358–371.e9.
21. Hui S, Ghergurovich JM, Morscher RJ, Jang C, Teng X, Lu W, et al. Glucose feeds the TCA cycle via circulating lactate. Nature 2017;551:115–8.
22. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MKK, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci 2006;103:13132–7.
23. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011;478:197–203.
24. Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 2015;162:1229–41.
25. Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D, et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab 2014;20:61–72.
26. Angelin A, Gil-de-Gómez L, Dahiya S, Jiao J, Guo L, Levine MH, et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab 2017;25:1282–1293.e7.
27. Andrejeva G, Rathmell JC. Similarities and distinctions of cancer and immune metabolism in inflammation and tumors. Cell Metab 2017;26: 49–70.
28. Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, et al. L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 2016;167:829–842.e13.
29. Ma EH, Bantug G, Griss T, Condotta S, Johnson RM, Samborska B, et al. Serine is an essential metabolite for effector T cell expansion. Cell Metab 2017;25:345–57.
30. Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, et al. The transcription factor myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 2011;35:871–82.
31. Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 2011;11:671–7.
32. Corbet C, Feron O. Tumour acidosis: from the passenger to the driver's seat. Nat Rev Cancer 2017;17:577–93.
33. Nakazawa MS, Keith B, Simon MC. Oxygen availability and metabolic adaptations. Nat Rev Cancer 2016;16:663–73.
34. Tannock IF, Rotin D. Acid pH in tumors and its potential for therpeutic exploitation. Cancer Res 1989;49:4373–84.
35. Gillies RJ, Liu Z, Bhujwalla Z. 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am J Physiol 1994;267: C195–203.
36. Hashim AI, Zhang X, Wojtkowiak JW, Martinez GV, Gillies RJ. Imaging pH and metastasis. NMR Biomed 2011;24:582–91.
37. Gillies RJ, Raghunand N, García-Martín ML, Gatenby RA. pH imaging. A review of pH measurement methods and applications in cancers. IEEE Eng Med Biol Mag 2004;23:57–64.
38. Zhang X, Lin Y, Gillies RJ. Tumor pH and its measurement. J Nucl Med 2010;51:1167–70.
39. Persi E, Duran-Frigola M, Damaghi M, Roush WR, Aloy P, Cleveland JL, et al. Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 2018;9.
40. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007;109:3812–20.
41. Michiels C, Tellier C, Feron O. Biochimica et Biophysica Acta Cycling hypoxia: a key feature of the tumor microenvironment. BBA - Rev Cancer 2016;1866:76–86.
42. Vaupel P, Mayer A.Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225–39.
43. Vaupel P, Höckel M, Mayer A. Detection and characterization of tumor hypoxia using pO 2 histography. Antioxid Redox Signal 2007;9:1221–36.
44. Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991;51:3316–22.
45. Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, et al. Imaging tumour hypoxia with positron emission tomography. Br J Cancer 2015;112:238–50.
46. Hammond EM, Asselin MC, Forster D, O'Connor JPB, Senra JM, Williams KJ. The meaning, measurement and modification of hypoxia in the laboratory and the clinic. Clin Oncol 2014;26:277–88.
47. Lu W, Su X, Klein MS, Lewis IA, Fiehn O, Rabinowitz JD. Metabolite measurement: pitfalls to avoid and practices to follow. Annu Rev Biochem 2017;86:277–304.
48. Jang C, Chen L, Rabinowitz JD. Metabolomics and isotope tracing. Cell 2018;173:822–37.
49. Yuneva MO, Fan TWM, Allen TD, Higashi RM, Ferraris DV, Tsukamoto T, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab 2012;15:157–70.
50. Davidson SM, Papagiannakopoulos T, Olenchock BA, Heyman JE, Keibler MA, Luengo A, et al. Environment impacts the metabolic dependencies of ras-driven non-small cell lung cancer. Cell Metab 2016;23:517–28.
51. Hensley CT, Faubert B, Yuan Q, Lev-Cohain N, Jin E, Kim J, et al. Metabolic heterogeneity in human lung tumors. Cell 2016;164:681–94.
52. Goveia J, Pircher A, Conradi L, Kalucka J, Lagani V, Dewerchin M, et al. Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities. EMBO Mol Med 2016;8:1134–42.
53. Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res 2015;75:544–53.

Downloaded from http://aacrjournals.org/cancerres/article-pdf/79/13/3155/2782852/3155.pdf by guest on 16 October 2024

54. Davidson SM, Jonas O, Keibler MA, Hou HW, Luengo A, Mayers JR, et al. Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors. Nat Med 2017;23:235–41.
55. Reznik E, Luna A, Aksoy BA, Liu EM, La K, Ostrovnaya I, et al. A landscape of metabolic variation across tumor types. Cell Syst 2018;1–13.
56. Haslene-Hox H, Tenstad O, Wiig H. Interstitial fluid - a reflection of the tumor cell microenvironment and secretome. Biochim Biophys Acta 2013; 1834:2336–46.
57. Leegsma-Vogt G, Janle E, Ash SR, Venema K, Korf J. Utilization of *in vivo* ultrafiltration in biomedical research and clinical applications. Life Sci 2003;73:2005–18.
58. Chatard C, Meiller A, Marinesco S. Microelectrode biosensors for *in vivo* analysis of brain interstitial fluid. Electroanalysis 2018;30:977–98.
59. Schroeder U, Himpe B, Pries R, Vonthein R, Nitsch S, Wollenberg B. Decline of lactate in tumor tissue after ketogenic diet: *in vivo* microdialysis study in patients with head and neck cancer. Nutr Cancer 2013;65:843–9.
60. Roslin M, Henriksson R, Bergström P, Ungerstedt U, Bergenheim AT. Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis. J Neurooncol 2003;61: 151–60.
61. Celis JE, Gromov P, Cabezón T, Moreira JMA, Ambartsumian N, Sandelin K, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment. Mol Cell Proteomics 2004;3:327–44.
62. Wiig H, Aukland K, Tenstad O. Isolation of interstitial fluid from rat mammary tumors by a centrifugation method. Am J Physiol Hear Circ Physiol 2003;284:H416–24.
63. Haslene-Hox H, Oveland E, Berg KC, Kolmannskog O, Woie K, Salvesen HB, et al. A new method for isolation of interstitial fluid from human solid tumors applied to proteomic analysis of ovarian carcinoma tissue. PLoS ONE 2011;6.
64. Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR, Sendor AB, et al. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight 2017;2:1–13.
65. Ho PC, Bihuniak JD, MacIntyre AN, Staron M, Liu X, Amezquita R, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T-cell responses. Cell 2015;162:1217–28.
66. Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang G, Hudaihed A, et al. Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell 2017;32:377–391.e9.
67. Liu MX, Jin L, Sun SJ, Liu P, Feng X, Cheng ZL, et al. Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma. Oncogene 2018;37:1637-1653.
68. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002;2:683–93.
69. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003;9:713–25.
70. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5: 436–46.
71. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927;8:519–30.
72. Sauer La, Iii JWS, Dauchy RT, Webster J. Amino acid, glucose, and lactic acid utilization *in vivo* by rat tumors1982;42:4090–7.
73. Sauer La, Dauchy RT. Ketone body, glucose, lactic acid, and amino acid utilization by tumors *in vivo* in fasted rats11983;3497–503.
74. Kallinowski F, Vaupel P, Runkel S, Berg G. Glucose uptake, lactate release, ketone body turnover, metabolic micromilieu, and pH distributions in human breast cancer xenografts in nude rats. Cancer Res 1988;48:7264–72.
75. Holm E, Staedt U, Schlickeiser G, Leweling H, Tokus M, Hagmüller E, et al. Substrate balances across colonic carcinomas in humans. Cancer Res 1995; 55:1373–8.
76. Richtsmeier WJ, Dauchy R, Sauer LA. *In vivo* nutrient uptake by head and neck cancers. Cancer Res 1987;47:5230–3.
77. Buescher JM, Antoniewicz MR, Boros LG, Burgess SC, Brunengraber H, Clish CB, et al. A roadmap for interpreting13C metabolite labeling patterns from cells. Curr Opin Biotechnol 2015;34:189–201.
78. Faubert B, DeBerardinis RJ. Analyzing tumor metabolism *in vivo*. Annu Rev Cancer Biol 2017;1:99–117.
79. Maher EA, Marin-Valencia I, Bachoo RM, Mashimo T, Raisanen J, Hatanpaa KJ, et al. Metabolism of [U-13C]glucose in human brain tumors *in vivo*. NMR Biomed 2012;25:1234–44.
80. Courtney KD, Bezwada D, Mashimo T, Pichumani K, Vemireddy V, Funk AM, et al. Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation *in vivo*. Cell Metab 2018;1–8.
81. Sellers K, Fox MP, Ii MB, Slone SP, Higashi RM, Miller DM, et al. Pyruvate carboxylase is critical for non–small-cell lung cancer proliferation. J Clin Invest 2015;125:687–98.
82. Fan TW, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, et al. Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM). Mol Cancer 2009;8:41.
83. Sonveaux P, Végran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008;118.
84. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PEZ, Harzstark AL, Ferrone M, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13 C] Pyruvate. Sci Transl Med 2013;5:198ra108.
85. Halestrap AP. The monocarboxylate transporter family-Structure and functional characterization. IUBMB Life 2012;64:1–9.
86. Barros LF, Deitmer JW. Glucose and lactate supply to the synapse. Brain Res Rev 2010;63:149–59.
87. Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK Cells. Cell Metab 2016;24:657–71.
88. Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res 2012;72:2746–56.
89. Sullivan MR, Danai LV, Lewis CA, Chan SH, Gui DY, Kunchok T, et al. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. Elife 2019;8. doi: 10.7554/eLife.44235.

Downloaded from http://aacrjournals.org/cancerres/article-pdf/79/13/3155/2782852/3155.pdf by guest on 16 October 2024